BACKGROUND: Little evidence is available about how quality of life (QoL) changes as dementia progresses. OBJECTIVES: We explored QoL trajectories over a 20-month period and examined what predicted change in QoL. METHOD: Fifty-one individuals with a diagnosis of Alzheimer's, vascular or mixed dementia (people with dementia (PwD)) participating in the Memory Impairment and Dementia Awareness Study rated their QoL using the QoL-Alzheimer's Disease Scale at baseline and at 20-month follow-up. PwD also rated their mood and quality of relationship with the carer. In each case, the carer rated his or her level of stress and perceived quality of relationship with the PwD. RESULTS: There was no change in mean QoL score. Nearly one-third of PwD rated QoL more positively at 20-month follow-up and nearly one-third rated QoL more negatively. These changes could be regarded as reliable in one-quarter of the sample. Participants taking acetylcholinesterase-inhibiting medication at baseline were more likely to show a decline in QoL score. There were no other significant differences between those whose scores increased, decreased or stayed the same on any demographic or disease-related variables, or in mood or perceived quality of relationship with the carer. Whereas baseline QoL score was the strongest predictor of QoL at 20 months, the quality of relationship with the carer as perceived by the PwD was also independently a significant predictor. CONCLUSIONS: There is a degree of individual variation in QoL trajectories. Use of acetylcholinesterase-inhibiting medication appears linked to decline in QoL score, whereas positive relationships with carers play an important role in maintaining QoL in early-stage dementia.
BACKGROUND: Little evidence is available about how quality of life (QoL) changes as dementia progresses. OBJECTIVES: We explored QoL trajectories over a 20-month period and examined what predicted change in QoL. METHOD: Fifty-one individuals with a diagnosis of Alzheimer's, vascular or mixed dementia (people with dementia (PwD)) participating in the Memory Impairment and Dementia Awareness Study rated their QoL using the QoL-Alzheimer's Disease Scale at baseline and at 20-month follow-up. PwD also rated their mood and quality of relationship with the carer. In each case, the carer rated his or her level of stress and perceived quality of relationship with the PwD. RESULTS: There was no change in mean QoL score. Nearly one-third of PwD rated QoL more positively at 20-month follow-up and nearly one-third rated QoL more negatively. These changes could be regarded as reliable in one-quarter of the sample. Participants taking acetylcholinesterase-inhibiting medication at baseline were more likely to show a decline in QoL score. There were no other significant differences between those whose scores increased, decreased or stayed the same on any demographic or disease-related variables, or in mood or perceived quality of relationship with the carer. Whereas baseline QoL score was the strongest predictor of QoL at 20 months, the quality of relationship with the carer as perceived by the PwD was also independently a significant predictor. CONCLUSIONS: There is a degree of individual variation in QoL trajectories. Use of acetylcholinesterase-inhibiting medication appears linked to decline in QoL score, whereas positive relationships with carers play an important role in maintaining QoL in early-stage dementia.
Authors: Linda Clare; Laura D Gamble; Anthony Martyr; Serena Sabatini; Sharon M Nelis; Catherine Quinn; Claire Pentecost; Christina Victor; Roy W Jones; Ian R Jones; Martin Knapp; Rachael Litherland; Robin G Morris; Jennifer M Rusted; Jeanette M Thom; Rachel Collins; Catherine Henderson; Fiona E Matthews Journal: J Gerontol B Psychol Sci Soc Sci Date: 2022-06-01 Impact factor: 4.942
Authors: Linda Clare; Sharon M Nelis; Catherine Quinn; Anthony Martyr; Catherine Henderson; John V Hindle; Ian R Jones; Roy W Jones; Martin Knapp; Michael D Kopelman; Robin G Morris; James A Pickett; Jennifer M Rusted; Nada M Savitch; Jeanette M Thom; Christina R Victor Journal: Health Qual Life Outcomes Date: 2014-11-30 Impact factor: 3.186
Authors: Hannah B Edwards; Sharea Ijaz; Penny F Whiting; Verity Leach; Alison Richards; Sarah J Cullum; Richard Il Cheston; Jelena Savović Journal: BMJ Open Date: 2018-01-21 Impact factor: 2.692
Authors: Marcia C Dourado; Maria F de Sousa; Raquel L Santos; José P Simões; Marcela L Nogueira; Tatiana T Belfort; Bianca Torres; Rachel Dias; Jerson Laks Journal: Braz J Psychiatry Date: 2016-01-08 Impact factor: 2.697
Authors: Linda Clare; Yu-Tzu Wu; Ian R Jones; Christina R Victor; Sharon M Nelis; Anthony Martyr; Catherine Quinn; Rachael Litherland; James A Pickett; John V Hindle; Roy W Jones; Martin Knapp; Michael D Kopelman; Robin G Morris; Jennifer M Rusted; Jeanette M Thom; Ruth A Lamont; Catherine Henderson; Isla Rippon; Alexandra Hillman; Fiona E Matthews Journal: Alzheimer Dis Assoc Disord Date: 2019 Jan-Mar Impact factor: 2.703